2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Profiling, Treatment Considerations, Combination Therapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

3485 NPM1 measurable residual disease kinetics in peripheral blood and marrow for patients with AML treated with intensive or lower-intensity therapy

Anika Patel, MD, Peter Carlsgaard, MD2, Ashwin Sunderraj, M.D.3, Ali Haider Mohamedi, MD4, Ashlyn O'Leary, MD5, Khaled AlBakri, MD6, Julia M. Anderson, BS, MS7, Gabino Escalada, MS8, Vivian Irizarry Gatell, MD9, Alejandro Marinos Velarde, MD10, Clayton Jackson, MD11, Shukaib Arslan, MD12, Lan Yu, MD13, Jing Xu, MD14, Dwight Oliver, MD15, Robert Collins, MD16, Stephen Chung, MD17, Yazan F. Madanat, MD18
1 UT Southwestern, Dallas, Texas, United States
2 UT Southwestern, Dallas, Texas, United States
3 UT Southwestern, Dallas, Texas, United States
4 UT Southwestern, Dallas, Texas, United States
5 UT Southwestern, Dallas, Texas, United States
6 UT Southwestern, Dallas, Texas, United States
7 UT Southwestern, Dallas, Texas, United States
8 UT Southwestern, Dallas, Texas, United States
9 UT Southwestern, Dallas, Texas, United States
10 UT Southwestern, Dallas, Texas, United States
11 UT Southwestern, Dallas, Texas, United States
12 UT Southwestern, Dallas, Texas, United States
13 UT Southwestern, Dallas, Texas, United States
14 UT Southwestern, Dallas, Texas, United States
15 UT Southwestern, Dallas, Texas, United States
16 UT Southwestern, Dallas, Texas, United States
17 UT Southwestern, Dallas, Texas, United States
18 UT Southwestern, Dallas, Texas, United States, UT Southwestern, Dallas, Texas, United States

Introduction 

NPM1-mutated (NPM1m) AML is one of the few AML subtypes with an established quantitative RT-qPCR assay for measurable residual disease (MRD) assessment. Persistence of NPM1 transcripts after treatment is associated with increased relapse risk; however, data regarding MRD kinetics, molecular relapse patterns, and MRD monitoring across different treatment intensities remain limited. We evaluated the clinical utility and kinetics of serial NPM1 MRD monitoring in patients with NPM1m AML treated at our institution. 

Methods 

We evaluated patients diagnosed with NPM1m AML treated at our institution from 2010 to 2025. NPM1 MRD testing on RNA was performed per institutional standard using an RT-PCR assay targeting NPM1 mutation types A, B, and D, with ABL1 RNA as a control transcript. Results were reported as normalized NPM1:ABL1 transcript ratios. The assay sensitivity was approximately 0.001% (1:100,000 cells). MRD negativity was defined as the first negative NPM1 PCR following a positive result. Molecular relapse was defined as reappearance of a positive NPM1 PCR after documented negativity. Bone marrow (BM) and peripheral blood (PB) samples obtained within seven days of one another were considered paired for concordance analyses. Descriptive statistics were used to evaluate MRD kinetics, BM/PB relationships, molecular relapse, and progression to morphologic relapse. Concurrent mutations were detected by NGS. 

Results 

Among 571 patients diagnosed with AML, 124 (21.7%) had NPM1m AML. Three patients were excluded due to incomplete records, leaving 121 evaluable patients. Median age at diagnosis was 60 years (range, 20-87.3), 58.7% were female, and 85.1% had de novo AML. Co-mutations included FLT3-ITD/TKD (37.1%), IDH1/2 (32.3%), DNMT3A (27.4%), KRAS/NRAS (17.7%), and TET2 (16.9%). Intensive chemotherapy (IC) was administered to 53% and lower-intensity therapy (LIT) to 47%. 

Ninety patients underwent at least one NPM1 MRD RT-qPCR assessment; 69 (76.6%) had serial monitoring (≥2 assays). A total of 727 MRD assessments were performed, with a median of six tests per patient (IQR, 3-14) over a median follow-up of 17.0 months (IQR, 6.8-29.0). Thirty-six patients (52%) achieved MRD negativity, with a median time to MRD clearance of 2.6 months. Twenty-two remained MRD-neg, whereas 14 (38.8%) experienced molecular relapse. Twenty-one paired BM/PB assessments with detectable transcripts in both compartments demonstrated strong correlation between PB and BM NPM1 levels (Pearson r=0.75, P<0.001). BM levels were typically higher than PB levels, with a median BM:PB ratio of 3.25-fold (approximately 0.5-log difference). Eleven additional paired assessments demonstrated BM-pos/PB-neg discordance. Overall, 34.4% of BM-pos assessments had a corresponding PB-neg result. Among patients with BM-pos/PB-neg discordance, 40% subsequently developed detectable PB MRD after a median of 116 days (3.8 months). Stratified analyses demonstrated median BM:PB ratios of 1.6-fold for PB levels <0.01%, 8.9-fold for PB levels between 0.01%-0.1%, and 2.3-fold for PB levels ≥0.1%. Among evaluable patients who subsequently developed morphologic relapse, molecular detection preceded morphologic relapse by a median of 190 days (6.2 months; range, 85-487 days). 

Conclusions 

In our single-center cohort, PB and BM MRD assessments demonstrated strong concordance, supporting PB as a practical tool for longitudinal monitoring in NPM1-mutated AML. However, substantial BM/PB variability exists, with approximately one-third of BM-pos assessments not detectable in PB, suggesting that PB cannot reliably predict the exact marrow disease burden in individual patients. Molecular relapse frequently preceded morphologic relapse by approximately six months, providing a clinically meaningful window for pre-emptive therapeutic intervention. Serial NPM1 MRD monitoring offers valuable insight into disease kinetics and may help guide relapse-directed strategies in NPM1m AML. 

Anika Patel, MD: No relevant conflicts of interest to declare.